Candel Q3 Loss Widens to $21.9M; Prostate Cancer BLA Slips to Mid-2027
CADL sits 93% above its 52-week low of $4.35.
Summary
Candel's Q3 net loss widened to $21.9 million on higher R&D, and the company now targets a mid-2027 BLA submission for aglatimagene in prostate cancer, later than previously expected. Cash of $203.1 million funds operations into Q2 2028.
Key Events · Earnings and Guidance · CADL
-
Q3 Loss Widens on R&D Step-Up
Net loss was $21.9 million versus $11.3 million a year earlier; R&D rose to $15.6 million from $8.5 million and G&A to $7.4 million from $4.7 million, driven by aglatimagene trial and manufacturing costs.
-
Prostate Cancer BLA Pushed to Mid-2027
Candel now plans to submit the aglatimagene BLA in the middle of 2027 pending FDA dialogue, citing timelines for certain assay refinement — a delay to the lead program's first approval path.
-
Cash Runway Extended to Q2 2028
Cash and cash equivalents were $203.1 million at September 30, 2026, up from $119.7 million at December 31, 2025, and management now expects funding into Q2 2028.
-
New SITC Data Across Three Programs
Updated linoserpaturev phase 1b data showed mOS of 12.0 months in Arms A+B (n=50) and 14.3 months in repeat-dosing Arm C (n=12); aglatimagene biomarker data showed systemic CD8+ T-cell activation.
Analysis · CADL · Life Sciences
The quarter itself is a cash-burn story: R&D jumped to $15.6 million from $8.5 million and the net loss nearly doubled to $21.9 million, driven by late-stage manufacturing and clinical work for aglatimagene. The bigger item is timing. Candel now plans to file its prostate cancer BLA in the middle of 2027 rather than sooner, citing assay refinement and ongoing FDA dialogue — pushing the first potential approval and any commercial revenue further out. Against that, cash rose to $203.1 million and management extended its runway estimate to Q2 2028 from Q1 2028, so the delay does not create near-term financing pressure. The stock's reaction will hinge on whether investors treat the BLA slip as a scheduling detail or a credibility hit on the company's lead asset.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CADL was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642M. The 52-week trading range was $4.35 to $14.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.